Although many studies have shown that NAbs reduce IFNβ efficacy, as measured by MRI and clinical disease activity [5,10,16-25], the clinical relevance of NAbs, especially at low titres, in MS patients treated with IFNβ remains debatable [26,27]. The gene discussed is IFNB1; the disease is myeloid sarcoma.